Nemvaleukin alfa Market Size, Forecast, and Emerging Insight - 2032
상품코드:1462304
리서치사:DelveInsight
발행일:On Demand Report
페이지 정보:영문 30 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
약제 요약
Nemvaloikin alfa(구 ALKS 4230)는 두경부암, 소세포폐암, 난소암, 난관암 등 고형암 치료제로 알커메스가 개발중인 인터루킨2 수용체 작용제입니다. 이 약물은 변형된 IL-2와 고친화도 IL-2α 수용체 사슬로 구성된 융합 단백질입니다. 이 조합은 종양을 파괴하는 면역세포를 증식시키는 반면, 중간 친화도의 IL-2 수용체 복합체에 우선적으로 결합하여 면역억제세포를 활성화하지 않도록 설계되었습니다. 이 약물의 선택성은 IL-2 요법의 항종양 효과를 높이면서 그 한계를 완화하기 위한 것입니다.
현재 플래티넘 제제 내성 난소암 치료제로 임상 3상(ARTISTRY-7)이 진행 중이며, 2025년 12월까지 완료될 예정입니다.
주요 7 시장(미국·독일·프랑스·이탈리아·스페인·영국·일본)의 난소암용 Nemvaleukin alfa에 대해 조사분석했으며, 작용기서, 용법과 용량, 연구개발 활동에 관한 인사이트, 매출의 예측 등을 제공하고 있습니다.
목차
제1장 리포트의 서론
제2장 난소암에서의 Nemvaleukin alfa 개요
제품의 상세
임상 개발
임상 연구
임상시험 정보
안전성과 유효성
기타 개발 활동
제품 개요
제3장 경쟁 구도(출시 치료법)
제4장 경쟁 구도(후기 신치료법)
제5장 Nemvaleukin alfa 시장 평가
난소암에서 Nemvaleukin alfa의 시장 전망
주요 7 시장 분석
주요 7 시장 난소암용 Nemvaleukin alfa의 시장 규모
시장 분석 : 국가별
미국의 난소암용 Nemvaleukin alfa의 시장 규모
독일의 난소암용 Nemvaleukin alfa의 시장 규모
영국의 난소암용 Nemvaleukin alfa의 시장 규모
제6장 SWOT 분석
제7장 애널리스트의 견해
제8장 부록
제9장 DelveInsight의 서비스 내용
제10장 면책사항
제11장 DelveInsight 소개
제12장 리포트 구입 옵션
KSA
영문 목차
영문목차
"Nemvaleukin alfa Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about nemvaleukin alfa for ovarian cancer in the seven major markets. A detailed picture of the nemvaleukin alfa for ovarian cancer in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the nemvaleukin alfa for ovarian cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the nemvaleukin alfa market forecast analysis for ovarian cancer in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.
Drug Summary:
Nemvaleukin alfa (previously known as ALKS 4230) is an interleukin-2 receptor agonist being developed by Alkermes for the treatment of solid tumors, including head and neck cancer, small cell lung cancer, ovarian cancer, fallopian tube cancer, and others. It is a fusion protein consisting of modified IL-2 and the high-affinity IL-2 alpha receptor chain. This combination is designed to expand tumor-destroying immune cells while not activating immunosuppressive cells by preferentially binding to the intermediate-affinity IL-2 receptor complex. The agent's selectivity is meant to mitigate limitations while boosting the anti-tumor effects of IL-2 therapy.
It is currently being investigated in Phase III clinical trial (ARTISTRY-7) for the potential treatment of Platinum-resistant Ovarian Cancer that is estimated to be completed by December 2025.
Scope of the Report:
The report provides insights into:
A comprehensive product overview including the nemvaleukin alfa description, mechanism of action, dosage and administration, research and development activities in ovarian cancer.
Elaborated details on nemvaleukin alfa regulatory milestones and other development activities have been provided in this report.
The report also highlights the nemvaleukin alfa research and development activities in ovarian cancer across the United States, Europe and Japan.
The report also covers the patents information with expiry timeline around nemvaleukin alfa.
The report contains forecasted sales of nemvaleukin alfa for ovarian cancer till 2032.
Comprehensive coverage of the late-stage emerging therapies for ovarian cancer.
The report also features the SWOT analysis with analyst views for nemvaleukin alfa in ovarian cancer.
Methodology:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Nemvaleukin alfa Analytical Perspective by DelveInsight
In-depth Nemvaleukin alfa Market Assessment
This report provides a detailed market assessment of nemvaleukin alfa for ovarian cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
Nemvaleukin alfa Clinical Assessment
The report provides the clinical trials information of nemvaleukin alfa for ovarian cancer covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights:
In the coming years, the market scenario for ovarian cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence nemvaleukin alfa dominance.
Other emerging products for ovarian cancer are expected to give tough market competition to nemvaleukin alfa and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of nemvaleukin alfa in ovarian cancer.
Our in-depth analysis of the forecasted sales data of nemvaleukin alfa from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the nemvaleukin alfa in ovarian cancer.
Key Questions:
What is the product type, route of administration and mechanism of action of nemvaleukin alfa?
What is the clinical trial status of the study related to nemvaleukin alfa in ovarian cancer and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the nemvaleukin alfa development?
What are the key designations that have been granted to nemvaleukin alfa for ovarian cancer?
What is the forecasted market scenario of nemvaleukin alfa for ovarian cancer?
What are the forecasted sales of nemvaleukin alfa in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
What are the other emerging products available and how are these giving competition to nemvaleukin alfa for ovarian cancer?
Which are the late-stage emerging therapies under development for the treatment of ovarian cancer?
